drugset / Trial / NCT00002482

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

NCT00002482

Treatment

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and cyclophosphamide in treating patients with metastatic cancer.

Timeline

Start
1991-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject muromonab-CD3 Monoclonal antibody